1. Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.
- Author
-
Spangler, Jamie B, Trotta, Eleonora, Tomala, Jakub, Peck, Ariana, Young, Tracy A, Savvides, Christina S, Silveria, Stephanie, Votavova, Petra, Salafsky, Joshua, Pande, Vijay S, Kovar, Marek, Bluestone, Jeffrey A, and Garcia, K Christopher
- Subjects
Cells ,Cultured ,Animals ,Humans ,Mice ,Colitis ,Autoimmune Diseases ,Disease Models ,Animal ,Receptors ,Interleukin-2 ,Recombinant Fusion Proteins ,Antibodies ,Cytokines ,Immunotherapy ,Protein Engineering ,Lymphocyte Activation ,Cell Proliferation ,T-Lymphocytes ,Regulatory ,Cells ,Cultured ,Disease Models ,Animal ,Receptors ,Interleukin-2 ,T-Lymphocytes ,Regulatory ,Immunology - Abstract
IL-2 has been used to treat diseases ranging from cancer to autoimmune disorders, but its concurrent immunostimulatory and immunosuppressive effects hinder efficacy. IL-2 orchestrates immune cell function through activation of a high-affinity heterotrimeric receptor (composed of IL-2Rα, IL-2Rβ, and common γ [γc]). IL-2Rα, which is highly expressed on regulatory T (TReg) cells, regulates IL-2 sensitivity. Previous studies have shown that complexation of IL-2 with the JES6-1 Ab preferentially biases cytokine activity toward TReg cells through a unique mechanism whereby IL-2 is exchanged from the Ab to IL-2Rα. However, clinical adoption of a mixed Ab/cytokine complex regimen is limited by stoichiometry and stability concerns. In this study, through structure-guided design, we engineered a single agent fusion of the IL-2 cytokine and JES6-1 Ab that, despite being covalently linked, preserves IL-2 exchange, selectively stimulating TReg expansion and exhibiting superior disease control to the mixed IL-2/JES6-1 complex in a mouse colitis model. These studies provide an engineering blueprint for resolving a major barrier to the implementation of functionally similar IL-2/Ab complexes for treatment of human disease.
- Published
- 2018